Empagliflozin-d4
CAY-22369-500 500 µg
Data Sheet: 
SDS:
SDS:
Formulation
A solid
Purity
≥99% deuterated forms (d1-d4)
MW
454,9
Shipment
-20
Long Term Storage
-20
Shelf Life
1460
Description
Empagliflozin-d4 is intended for use as an internal standard for the quantification of empagliflozin (Item No. 17375) by GC- or LC-MS. Empagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor (IC50 = 3.1 nM for the human transporter).{29653} It is selective for SGLT2 over SGLT1, -4, -5, and -6 (IC50s = 8.3, 11, 1.1, and 2 µM, respectively). Dietary administration of empagliflozin (0.03% for 10 weeks) reduces non-fasting blood glucose levels, as well as aortic superoxide levels and cardiac interstitial fibrosis, in db/db mice.{64264} It also decreases the severity of glomerulosclerosis, as well as reduces the escape latency in the Morris water maze, in the same model. Formulations containing empagliflozin have been used in the treatment of type 2 diabetes.
ESCLUSIVAMENTE PER USO DI RICERCA (RUO) e non per uso terapeutico o diagnostico su uomini o animali. Il prodotto NON è un Dispositivo Medico o un Diagnostico in Vitro.
PRODUCT FOR RESEARCH USE ONLY (RUO) and not for therapeutic or diagnostic use on humans or animals. The product is NOT a Medical Device or an In-Vitro Diagnostic (IVD).
